Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 6/20 | 0.45 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592453 | 0.72 | GPR35 (0.43) | GPR17RNASEH1 | |
| SCHEMBL7596983 | 0.71 | KDM4A (0.45) | GPR17GRIN1KDM4AKDM5AKDM5B | |
| SCHEMBL7817673 | 0.70 | MCL1 (0.48) | GPR17GRIN1 | |
| SCHEMBL7072708 | 0.69 | GPR17 (0.61) | GPR17 | |
| SCHEMBL7682574 | 0.68 | KDM4A (0.43) | GPR17RNASEH1KDM4AKDM5AKDM5B | |
| SCHEMBL7680945 | 0.68 | PTPRC (0.44) | GPR17RNASEH1KDM4AKDM5AKDM5B | |
| SCHEMBL8095087 | 0.68 | RNASEH1 (0.42) | GPR17RNASEH1GRIN1KDM4AKDM5A | |
| SCHEMBL7842628 | 0.68 | KDM4E (0.47) | — | |
| SCHEMBL7074236 | 0.67 | POLB (0.47) | — | |
| SCHEMBL7076761 | 0.66 | MCL1 (0.48) | GPR17RNASEH1FBP1KDM4AKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252142-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001051466-A1 | INDOLE DERIVATIVES AS MCP-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-07-19 | — | — | WO | disclosed |